GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » EV-to-EBIT

Moberg Pharma AB (OSTO:MOB) EV-to-EBIT : -23.87 (As of May. 28, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Moberg Pharma AB's Enterprise Value is kr634.07 Mil. Moberg Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-26.56 Mil. Therefore, Moberg Pharma AB's EV-to-EBIT for today is -23.87.

The historical rank and industry rank for Moberg Pharma AB's EV-to-EBIT or its related term are showing as below:

OSTO:MOB' s EV-to-EBIT Range Over the Past 10 Years
Min: -107.67   Med: 6.72   Max: 217.17
Current: -23.87

During the past 13 years, the highest EV-to-EBIT of Moberg Pharma AB was 217.17. The lowest was -107.67. And the median was 6.72.

OSTO:MOB's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs OSTO:MOB: -23.87

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Moberg Pharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr597.72 Mil. Moberg Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-26.56 Mil. Moberg Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -4.44%.


Moberg Pharma AB EV-to-EBIT Historical Data

The historical data trend for Moberg Pharma AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB EV-to-EBIT Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.62 -6.94 -6.98 -5.62 -14.70

Moberg Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.35 -2.01 -3.64 -14.70 -22.50

Competitive Comparison of Moberg Pharma AB's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's EV-to-EBIT falls into.



Moberg Pharma AB EV-to-EBIT Calculation

Moberg Pharma AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=634.073/-26.561
=-23.87

Moberg Pharma AB's current Enterprise Value is kr634.07 Mil.
Moberg Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-26.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OSTO:MOB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Moberg Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-26.561/597.7239
=-4.44 %

Moberg Pharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr597.72 Mil.
Moberg Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-26.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (OSTO:MOB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.